SciSparc Ltd. and Clearmind Medicine Inc. announced the publication of an international patent application for their innovative combination treatment of MDMA with N-Acylethanolamines. The collaboration aims to enhance both safety and therapeutic efficacy in treating mental health disorders and addictions.The partnership has already resulted in thirteen patents filed with the U.S. Patent and Trademark Office and other global jurisdictions. The novel approach combines psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA), potentially addressing FDA's safety concerns regarding MDMA treatments.CEO Oz Adler emphasized that this development demonstrates their commitment to offering effective and safe treatments. The combination therapy represents a strategic approach to overcome regulatory barriers while maximizing MDMA's therapeutic potential in clinical settings for mental health and addiction treatment.

SciSparc Ltd. and Clearmind Medicine Inc. announced the publication of an international patent application for their innovative combination treatment of MDMA with N-Acylethanolamines. The collaboration aims to enhance both safety and therapeutic efficacy in treating mental health disorders and addictions.The partnership has already resulted in thirteen patents filed with the U.S. Patent and Trademark Office and other global jurisdictions. The novel approach combines psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA), potentially addressing FDA's safety concerns regarding MDMA treatments.CEO Oz Adler emphasized that this development demonstrates their commitment to offering effective and safe treatments. The combination therapy represents a strategic approach to overcome regulatory barriers while maximizing MDMA's therapeutic potential in clinical settings for mental health and addiction treatment.